Região do Sul da Ordem dos Médicos - OMSUL - Profissionais de saúdehttps://http%3a%2f%2fwww.omsul.ptRSS document<![CDATA[ECDC - Rapid risk assessment: Assessing SARS-CoV-2 circulation, variants of concern, non-pharmaceutical interventions and vaccine rollout in the EU/EEA, 15th update]]>https://www.omsul.pt/noticias/ecdc-rapid-risk-assessment-assessing-sars-cov-2-circulation-variants-of-concern-non-pharmaceutical-interventions-and-vaccine-rollout-in-the-eueea-15th-updateMon, 26 Jul 2021 09:30:00 GMThttps://www.omsul.pt/noticias/ecdc-rapid-risk-assessment-assessing-sars-cov-2-circulation-variants-of-concern-non-pharmaceutical-interventions-and-vaccine-rollout-in-the-eueea-15th-update<![CDATA[ECDC - Countering online vaccine misinformation in the EU/EEA]]>https://www.omsul.pt/noticias/ecdc-countering-online-vaccine-misinformation-in-the-eueeaMon, 26 Jul 2021 09:28:00 GMThttps://www.omsul.pt/noticias/ecdc-countering-online-vaccine-misinformation-in-the-eueea<![CDATA[JAMA - SARS-CoV-2–Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women]]>https://www.omsul.pt/noticias/jama-sars-cov-2-specific-antibodies-in-breast-milk-after-covid-19-vaccination-of-breastfeeding-womenMon, 26 Jul 2021 09:26:00 GMThttps://www.omsul.pt/noticias/jama-sars-cov-2-specific-antibodies-in-breast-milk-after-covid-19-vaccination-of-breastfeeding-women<![CDATA[NEJM - Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant]]>https://www.omsul.pt/noticias/nejm-effectiveness-of-covid-19-vaccines-against-the-b16172-delta-variantMon, 26 Jul 2021 09:24:00 GMThttps://www.omsul.pt/noticias/nejm-effectiveness-of-covid-19-vaccines-against-the-b16172-delta-variant<![CDATA[BMJ - Covid-19 vaccines for children: hypothetical benefits to adults do not outweigh risks to children]]>https://www.omsul.pt/noticias/bmj-covid-19-vaccines-for-children-hypothetical-benefits-to-adults-do-not-outweigh-risks-to-childrenMon, 26 Jul 2021 09:23:00 GMThttps://www.omsul.pt/noticias/bmj-covid-19-vaccines-for-children-hypothetical-benefits-to-adults-do-not-outweigh-risks-to-children<![CDATA[NEJM - Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines]]>https://www.omsul.pt/noticias/nejm-prevention-and-attenuation-of-covid-19-with-the-bnt162b2-and-mrna-1273-vaccinesMon, 26 Jul 2021 09:21:00 GMThttps://www.omsul.pt/noticias/nejm-prevention-and-attenuation-of-covid-19-with-the-bnt162b2-and-mrna-1273-vaccines<![CDATA[NEJM - Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19]]>https://www.omsul.pt/noticias/nejm-bamlanivimab-plus-etesevimab-in-mild-or-moderate-covid-19Mon, 26 Jul 2021 09:19:00 GMThttps://www.omsul.pt/noticias/nejm-bamlanivimab-plus-etesevimab-in-mild-or-moderate-covid-19<![CDATA[ECDC - Threat Assessment Brief: Implications for the EU/EEA on the spread of the SARS-CoV-2 Delta (B.1.617.2) variant of concern]]>https://www.omsul.pt/noticias/ecdc-threat-assessment-brief-implications-for-the-eueea-on-the-spread-of-the-sars-cov-2-delta-b16172-variant-of-concernMon, 26 Jul 2021 09:18:00 GMThttps://www.omsul.pt/noticias/ecdc-threat-assessment-brief-implications-for-the-eueea-on-the-spread-of-the-sars-cov-2-delta-b16172-variant-of-concern<![CDATA[ECDC - Indicator framework to evaluate the public health effectiveness of digital proximity tracing solutions]]>https://www.omsul.pt/noticias/ecdc-indicator-framework-to-evaluate-the-public-health-effectiveness-of-digital-proximity-tracing-solutionsMon, 26 Jul 2021 09:15:00 GMThttps://www.omsul.pt/noticias/ecdc-indicator-framework-to-evaluate-the-public-health-effectiveness-of-digital-proximity-tracing-solutions<![CDATA[CDC - Interim Guidance for Antigen Testing for SARS-CoV-2]]>https://www.omsul.pt/noticias/cdc-interim-guidance-for-antigen-testing-for-sars-cov-2Mon, 26 Jul 2021 09:13:00 GMThttps://www.omsul.pt/noticias/cdc-interim-guidance-for-antigen-testing-for-sars-cov-2